280 related articles for article (PubMed ID: 21931707)
1. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer.
Wang L; Chen H; Liu F; Madigan MC; Power CA; Hao J; Patterson KI; Pourgholami MH; O'Brien PM; Perkins AC; Li Y
Cancer Lett; 2011 Jan; 300(2):122-33. PubMed ID: 21075513
[TBL] [Abstract][Full Text] [Related]
3. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
Song EY; Qu CF; Rizvi SM; Raja C; Beretov J; Morgenstern A; Apostolidis C; Bruchertseifer F; Perkins A; Allen BJ
Cancer Biol Ther; 2008 Jan; 7(1):76-80. PubMed ID: 18347423
[TBL] [Abstract][Full Text] [Related]
4. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
[TBL] [Abstract][Full Text] [Related]
7. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
8. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Yokoyama Y; Xin B; Shigeto T; Mizunuma H
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
[TBL] [Abstract][Full Text] [Related]
9. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
10. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
11. Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel.
Feng LX; Li M; Liu YJ; Yang SM; Zhang N
Int J Mol Sci; 2014 Mar; 15(3):4201-20. PubMed ID: 24619193
[TBL] [Abstract][Full Text] [Related]
12. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y
Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732
[TBL] [Abstract][Full Text] [Related]
13. A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance.
Su X; Gao C; Shi F; Feng X; Liu L; Qu D; Wang C
Drug Deliv; 2017 Nov; 24(1):10-19. PubMed ID: 28155336
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
15. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer.
De Souza R; Zahedi P; Moriyama EH; Allen CJ; Wilson BC; Piquette-Miller M
Mol Cancer Ther; 2010 Jun; 9(6):1820-30. PubMed ID: 20530719
[TBL] [Abstract][Full Text] [Related]
16. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.
Kaimal R; Aljumaily R; Tressel SL; Pradhan RV; Covic L; Kuliopulos A; Zarwan C; Kim YB; Sharifi S; Agarwal A
Cancer Res; 2013 Apr; 73(8):2457-2467. PubMed ID: 23423981
[TBL] [Abstract][Full Text] [Related]
17. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
19. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
Miller RE; Roudier M; Jones J; Armstrong A; Canon J; Dougall WC
Mol Cancer Ther; 2008 Jul; 7(7):2160-9. PubMed ID: 18606716
[TBL] [Abstract][Full Text] [Related]
20. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
